Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study.
about
Nicotine for schizophreniaNicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders.Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disordersVarenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized TrialnAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Chronic nicotine improves short-term memory selectively in a G72 mouse model of schizophrenia.Effects of nicotine on attention and inhibitory control in healthy nonsmokers.Effects of transdermal nicotine on episodic memory in non-smokers with and without schizophrenia.Reverse translation of the rodent 5C-CPT reveals that the impaired attention of people with schizophrenia is similar to scopolamine-induced deficits in miceNicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptorEffects of moderate-dose treatment with varenicline on neurobiological and cognitive biomarkers in smokers and nonsmokers with schizophrenia or schizoaffective disorder.Correlation of prepulse inhibition and Wisconsin Card Sorting Test in schizophrenia and controls: effects of smoking statusSubtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measuresSmoking, Genetics and Schizophrenia: Evidence for Self Medication.Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.Risk/reward decision-making in schizophrenia: a preliminary examination of the influence of tobacco smoking and relationship to Wisconsin Card Sorting Task performancePredictors of early abstinence in smokers with schizophreniaThe effects of galantamine on psychopathology in chronic stable schizophrenia.The interactive effects of ketamine and nicotine on human cerebral blood flowCo-morbidity of smoking in patients with psychiatric and substance use disorders.Alpha7 nicotinic acetylcholine receptor: a link between inflammation and neurodegeneration.Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophreniaInitial phase 2 trial of a nicotinic agonist in schizophrenia.Pharmacological treatment effects on eye movement controlCognitive effects of very low nicotine content cigarettes, with and without nicotine replacement, in smokers with schizophrenia and controlsEye tracking dysfunction in schizophrenia: characterization and pathophysiology.Eye movement dysfunction in first-degree relatives of patients with schizophrenia: a meta-analytic evaluation of candidate endophenotypes.The antisaccade task as a research tool in psychopathology: a critical review.Cholinergic circuits and signaling in the pathophysiology of schizophreniaRecent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.Comparison of the effectiveness of Conners' CPT and the CPT-identical pairs at distinguishing between smokers and nonsmokers with schizophrenia.Medications Development for the Treatment of Nicotine Dependence in Individuals with Schizophrenia.Chronic nicotine improves cognitive performance in a test of attention but does not attenuate cognitive disruption induced by repeated phencyclidine administration.A test of the cognitive self-medication hypothesis of tobacco smoking in schizophrenia.Acute nicotine administration effects on fractional anisotropy of cerebral white matter and associated attention performanceAcute nicotine improves social decision-making in non-smoking but not in smoking schizophrenia patientsThe tell-tale tasks: a review of saccadic research in psychiatric patient populations.Mechanisms underlying the comorbidity of tobacco use in mental health and addictive disorders.Neuropsychological performance in patients with schizophrenia and controls as a function of cigarette smoking status.
P2860
Q24244830-7E47ACD7-F6BF-4008-AB86-9E30A8BA93D5Q24532028-B4E8B508-6FDC-4A44-8907-081287B90F54Q28263028-F5D3F0B3-55B6-4DBC-BA7E-C531E4075453Q28552053-81A1DC74-4E3A-4A7A-9208-6BF281F05A15Q30362464-54E3A4B7-A50E-4A77-8F19-862AC74F1A8BQ30415168-76AA6D9C-FC0C-4366-9C29-ADE39C50F30EQ30422977-3DD3F14D-94AE-49A6-8A6E-86C8BD805638Q30435496-8733EC1B-7583-4DA7-8B1A-80669AF99CCFQ30446313-579D2306-92C7-4789-8AD1-37ACDAE9B680Q30453198-1F0A0E9B-4ADE-4338-A28A-F7E2C9087FFBQ30455599-B92FDD21-CBCF-499C-87D2-A709C41C48B3Q30479419-6F9DBA93-594F-44E6-A48C-FAFE6252215BQ30487079-FE87E23A-5CB8-4FEF-A2EF-BA1823A92104Q30491325-FA9F283C-A6F5-46FA-B2EE-7F35B63E3C20Q30491841-AABF5A26-86D5-404C-8248-2C83A2EFE5CAQ30493072-199EAFE2-5E88-4A75-9873-27C58B8604DAQ33635728-AE38120C-6305-4F25-8E5B-4DA6E9C5E727Q33679772-A60652CD-8E15-4170-BDE4-B0A0F22AFC00Q33724801-E90DC555-6BC2-4AE2-A8CF-3B9EBA0F3249Q33937889-F439B018-C04F-4232-936A-0E3BE41DF85FQ33942653-E9863B8D-9E55-4DE4-80DB-5932DF7FBDC1Q33955075-5C9AFB1C-E9C1-45A0-BFBD-BE31C66A71F0Q34604413-F31FDA6D-03A4-4A5F-BC9A-27E5E13AC65FQ34766663-9E85E333-EC1E-4269-9FFC-0B7B21831E8CQ35173870-9B59C2E3-2426-4CBE-965B-E512DE89AA79Q35473864-C14CDA3F-32ED-4155-8E4E-CF61BE61F76EQ35539209-8B560FBF-5D94-4B30-B13D-2C42D28E8D90Q36304346-A3CEC055-ABC5-496F-B9C6-317DBDC6E84EQ36522001-5AA2755C-7FF5-40DC-B2BB-CAB80F275A70Q36756379-35951BC4-6FF8-49BC-BB8F-4B687FB22675Q36886717-051EC822-ECAE-440E-BC32-CCB57A084F11Q37067243-DDA5D989-FEDC-476D-9FCC-50C83B0DCC39Q37079797-11083149-7968-4F52-83E0-44810A3F9CACQ37081349-F7A2B6C8-EDE6-4B28-8679-4CD48CB1C06AQ37127723-DF5D0C49-E5CB-4636-AC38-DF104D1F916EQ37180050-08017B20-8307-45B9-83AB-9BD6E78C10B7Q37267275-F8F4AEB8-E25A-4FEA-9BF2-C608D87B2F92Q37308096-7D49D2C9-36AE-4815-B036-17F06C7956E3Q37519956-28128776-151D-4113-A676-51B71D87A6C9Q37693834-8EDA86CD-F4E3-487F-8F7C-A3DA6C5966FE
P2860
Nicotine and behavioral markers of risk for schizophrenia: a double-blind, placebo-controlled, cross-over study.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Nicotine and behavioral marker ...... -controlled, cross-over study.
@en
Nicotine and behavioral marker ...... -controlled, cross-over study.
@nl
type
label
Nicotine and behavioral marker ...... -controlled, cross-over study.
@en
Nicotine and behavioral marker ...... -controlled, cross-over study.
@nl
prefLabel
Nicotine and behavioral marker ...... -controlled, cross-over study.
@en
Nicotine and behavioral marker ...... -controlled, cross-over study.
@nl
P2093
P1476
Nicotine and behavioral marker ...... -controlled, cross-over study.
@en
P2093
Anne-Lise V Holahan
Gillian A O'Driscoll
Joseph X Thavundayil
Lana Dépatie
N Ng Ying Kin
Samarthji Lal
Victoria Atkinson
P304
P356
10.1016/S0893-133X(02)00372-X
P407
P577
2002-12-01T00:00:00Z
P6179
1038357716